TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Score on UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Relapse After Discontinuation of RLAI
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants who Relapsed After Discontinuation of RLAI
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in PANSS Total Score After Re-Initiation of RLAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute neutrophil count in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Radiographic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti proliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall state of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Excreting Resistant Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Utility-weighted modified Rankin Scale (uw-mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of local and distant recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Functional outcome based on constant and neer score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Score of severity of Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the study device
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the receiver-operator characteristic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of Neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Height at the end of two years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state plasma and intracellular concentrations of darunavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulative excretion rate of SHR0302 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of immune cells and cytokines (IL-6, IL-10, IL-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Achieve Target MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IKDC knee function subjective evaluation form score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Patients Hospitalized
Endpoint domain: Adverse events/effects
Primary endpoint: Food Intake (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically-validated 7-day point prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Ideal Body Weight (%IBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to clinical improvement (TTIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive improvement from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of participants achieving inhibitor titer < 0.6 BU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants achieving FVIII recovery ≥ 66% of reference value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants achieving FVIII half-life ≥ 6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Annualized bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Performance of radiomics tool in characterizing lung nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of INO-1001
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular Death or Hospitalization for Worsening Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Breathing patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ease of gathering short speech recordings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient preferences for recording
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: number of subjects with cure or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sensitivity of se-S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of se-S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of se-S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of se-S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear growth (height during childhood)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroduodenal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cumulative incidence of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Area under the steady state concentration-time curve of linagliptin in plasma (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured steady state concentration of linagliptin in plasma (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of job loss
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Brain dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients referred for Sudden Cardiac Death Risk Stratification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of Serum 25 OHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Intensity Difference (PID)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Single procedural success rate (free from AF off anti-arrhythmic drugs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant HIV Seroconversions
Endpoint domain: Mortality/survival
Primary endpoint: Average change in luteinizing hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Implementation of Obstetric Hemorrhage Bundle Components
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Changes of ABC-J Irritability Subscale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction before discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of performance and placement tests for predicting SAD position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 measured by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PEFR measured by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of puffs/day of rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dehydroepiandrosterone sulfate (DHEAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Androstenedione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sex hormone binding globulin (SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Free testosterone index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in mean macular sensitivity (dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of risk factors for severe asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of the IRX-2 Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour systolic BP profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time interval between measurement of cervical length and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in symptoms of bipolar depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient and caregiver competency scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Response Rate Per RECIST Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality at 60 days post amputation procedure
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge score of HIV
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline somatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Clinically Meaningful Prolongation of the QT Interval Corrected for Heart Rate (QTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in QTc From Time-matched Baseline Assessed Using Fridericia's Correction Formula (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood Absolute Eosinophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Brain Nicotine Area Under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Brain Nicotine Maximum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in T1/2 of Brain Nicotine Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Initial Slope of Brain Nicotine Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: intercellular adhesion molecule-1 (ICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disability of the Arm, Shoulder and Hand score (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time in Range 70-180%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants for whom dose volume treatment planning constraints are not met
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants having measured breast skin dose => 110% of the prescribed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants scoring =>6 on the CTCAE Version 4.0 skin assessment
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD clinical symptoms-parent rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD clinical symptoms-teacher rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median muscular load of the bilateral trapezius pars descendens muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Static muscular load of the bilateral trapezius pars descendens muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sustained muscular activity of the bilateral trapezius pars descendens muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular rest time of the bilateral trapezius pars descendens muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of surgical smoke obstructing vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of lateral thermal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose normalized area under plasma concentration-time curve from time zero to infinity (AUC/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose normalized area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose normalized maximum observed plasma concentration (Cmax/D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of administered selumetinib granule dose systemically available relative to the capsule reference (Frel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of analgesics
Endpoint domain: Adverse events/effects
Primary endpoint: Number of optimum tube selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reintubation due to large or small tube
Endpoint domain: Adverse events/effects
Primary endpoint: Significant complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nociception-specific Brain Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the Periodic Limb Movements in Sleep associated with Arousal/hour of sleep (PLMAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in sleep Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ceftazidime plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avibactam plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ceftazidime effluent concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avibactam effluent concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Cord engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Symptomatic Virologically Confirmed Dengue Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adequate control of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate control of LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequate control of glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Medication Errors at Hospital Discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers of CD8+ T cells within the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number Line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NLR and PLR ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of prescribing for efficacious therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of cerebral palsy subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accurate diagnosis of NSTEMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Investigator's global assessment of disease activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Scale-17 (HAMD-17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Cognitive Assessment Tool for schizophrenia (B-CATS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spine ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional recovery after Achilles tendon rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from subjective pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from hyperalgesia periincisional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of use of the device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in dnDSA development (PRE-TX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in dnDSA development (POST-TX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Graft Survival (PRE-TX)
Endpoint domain: Mortality/survival
Primary endpoint: Graft Survival (POST-TX)
Endpoint domain: Mortality/survival
Primary endpoint: Change in depressive level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptomatic urinary infections
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically valuable CACT perfusion images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Lumbar Spine Repositioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women receiving influenza vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of women receiving pertussis vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timely childhood vaccinations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in Raven's advanced progressive matrices
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients assigned specific diagnoses or syndromic classifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Double leg support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Balance skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-regional Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Total score on the Montgomery Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General prevalence of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Serum biomarkers associated with BD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demethylation differences between ocular and non-ocular BD participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically relevant findings in 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with clinically relevant findings in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in rhinoscopy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of sperm retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Development of large esophageal varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in 24-hour blood glucose profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Improved Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axillary block efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Time of Blood Glucose in Range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes